54 search results for: coexisting diseases

ERS 2026 | Breaking Silos Between Asthma and CRSwNP: Loss of Smell as a Marker of Unified Airway Disease
Pulmonology
ERS 2026 | Breaking Silos Between Asthma and CRSwNP: Loss of Smell as a Marker of Unified Airway Disease
expert video

Join experts Roland Buhl, Joaquim Mullol, and Giselle Mosnaim as they discuss the role of type 2 inflammation across the unified airway, with a focus on the amplified burden and the difficulty controlling inflammation when asthma and CRSwNP coexist.

View more
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma
Pulmonology
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma
expert video

Join experts Frederik Trinkmann, Monica Kraft, and Arnaud Bourdin on an ADVENT educational symposium, “Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma."

View more
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
Dermatology
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.

View more
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Dermatology
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
expert video

Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.

View more
Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.

View more
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
Dermatology
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
expert video

This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.

View more